Diet/Growth Factor Mechanisms of Gut Adaptation - Full Text View

Sponsored by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:	NCT00067860

Purpose

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.

Condition	Intervention	Phase
Short Bowel Syndrome	Drug: recombinant human growth hormone Behavioral: diet modification	Phase II

MedlinePlus related topics: Diets

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Diet/Growth Factor Mechanisms of Gut Adaptation

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment:	30
Study Start Date:	October 1996
Study Completion Date:	December 2006
Primary Completion Date:	December 2006 (Final data collection date for primary outcome measure)

Detailed Description:

This is a double-blind randomized controlled study on the clinical and metabolic effects and underlying gut mucosal mechanisms of modified diet, with or without recombinant human growth hormone, in adults with severe short bowel syndrome dependent upon parenteral nutrition. Clinical endpoints include ability to wean patients from parenteral feeding, metabolic endpoints include gut nutrient absorptive function and molecular endpoints include expression of growth factors and nutrient transporters in small bowel and colonic mucosa. The 6-month study is performed, in part, in the General Clinical Research Center for inpatient stays and outpatient visits.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Parenteral nutrition-dependent adults with short gut syndrome.
Patients must not have diabetes mellitus or active malignancy within the past 5 years.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067860

Locations

United States, Georgia
Emory University School of Medicine
Atlanta, Georgia, United States, 30322

Sponsors and Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

Principal Investigator:

Thomas R Ziegler, MD

Emory University

More Information

No publications provided

Study ID Numbers:	DGFMGA DK55850, DK55850
Study First Received:	August 29, 2003
Last Updated:	January 8, 2008
ClinicalTrials.gov Identifier:	NCT00067860 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Digestive System Diseases
Postoperative Complications
Gastrointestinal Diseases
Mitogens

Malabsorption Syndromes
Short Bowel Syndrome
Intestinal Diseases
Hormones

Additional relevant MeSH terms:

Disease
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Mitosis Modulators
Short Bowel Syndrome
Intestinal Diseases
Pharmacologic Actions

Digestive System Diseases
Pathologic Processes
Postoperative Complications
Syndrome
Malabsorption Syndromes
Mitogens

ClinicalTrials.gov processed this record on May 07, 2009